← Leaderboards
John Peter Wikswo
Vanderbilt University
$17,124,536
Attributed
$33,824,697
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$33,824,697 · 10
By mechanism
U01$12,879,237 · 2
UH3$8,365,914 · 2
R01$3,953,482 · 1
RC2$2,661,005 · 1
UG3$2,454,302 · 1
UH2$2,216,030 · 1
Top collaborators
- Donna J Webb9 shared
- Damir Janigro8 shared
- Kevin C Ess7 shared
- Chaitali Ghosh6 shared
- Maja Diana Neely6 shared
- William L Murphy5 shared
- D. Lansing Taylor5 shared
- Kevin D Niswender3 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Kevin C Ess$5,903,437
- Rebecca A Ihrie$3,076,040
- Franz Josef Baudenbacher$1,362,175
- Maja Diana Neely$2,145,567
- Laura Catherine Geben$67,298
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsResponseAffectPharmaceutical PreparationsTechnologyDesignSignal TransductionNeurovascular UnitBrainEnsureIn VitroMolecularDrug EfficacyDevicesMetabolicInstrumentClinical TrialsCell TypeBiologicalCoupledMicrofluidicsIon MobilityMetabolismMass Spectrum Analysis
Grant awards (45)
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma$1,492,261
U01 · FY2022 · TR · contact PI
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma$1,510,763
U01 · FY2021 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,149,180
UH3 · FY2021 · TR · contact PI
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma$1,536,934
U01 · FY2020 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,149,938
UH3 · FY2020 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,142,940
UH3 · FY2020 · TR · contact PI
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma$1,530,740
U01 · FY2019 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,156,801
UH3 · FY2019 · TR · contact PI
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanoma$1,571,990
U01 · FY2018 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,046,419
UG3 · FY2018 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$261,603
UG3 · FY2018 · TR · contact PI
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological models$1,146,280
UG3 · FY2017 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$1,055,232
UH3 · FY2016 · TR · contact PI
Neurovascular Unit on a Chip: Regional Chemical Communication, Drug and Toxin Responses$156,014
UH3 · FY2016 · TR · contact PI
Neurovascular Unit on a Chip: Regional Chemical Communication, Drug and Toxin Responses$72,800
UH3 · FY2016 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$1,055,232
UH3 · FY2015 · TR · contact PI
Neurovascular Unit on a Chip: Regional Chemical Communication, Drug and Toxin Responses$235,494
UH3 · FY2015 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$137,051
UH3 · FY2015 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$1,055,232
UH3 · FY2014 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$1,012,882
UH2 · FY2013 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$145,500
UH2 · FY2013 · TR · contact PI
Neurovascular Unit on a Chip: Chemical Communication, Drug and Toxin Responses$1,057,648
UH2 · FY2012 · TR · contact PI
Elucidation of Leukocyte and Macrophage Biomarker Signatures from Drugs of Abuse$1,169,938
RC2 · FY2010 · DA
Correlative Multimodal Imaging of Cardiac Electrophysiology and Metabolism$540,275
R01 · FY2010 · HL · contact PI
Automated Microscope for Long-Duration, Quantitative Dynamic Imaging$500,000
S10 · FY2010 · RR · contact PI
Elucidation of Leukocyte and Macrophage Biomarker Signatures from Drugs of Abuse$1,491,067
RC2 · FY2009 · DA
Metabolic Discrimination of Unknown Bacterial Pathogens$1,079,130
U01 · FY2009 · AI · contact PI
Correlative Multimodal Imaging of Cardiac Electrophysiology and Metabolism$566,138
R01 · FY2009 · HL · contact PI
Metabolic Discrimination of Unknown Bacterial Pathogens$1,047,698
U01 · FY2008 · AI · contact PI
Bioengineering$194,811
U54 · FY2008 · CA · contact PI
Metabolic Discrimination of Unknown Bacterial Pathogens$1,036,884
U01 · FY2007 · AI · contact PI
Electrophysiological Implications of Cardiac Bidomain$400,075
R01 · FY2007 · HL · contact PI
Bioengineering$192,063
U54 · FY2007 · CA · contact PI
Metabolic Discrimination of Unknown Bacterial Pathogens$995,605
U01 · FY2006 · AI · contact PI
Electrophysiological Implications of Cardiac Bidomain$417,835
R01 · FY2006 · HL · contact PI
Bioengineering$127,780
U54 · FY2006 · CA · contact PI
Metabolic Discrimination of Unknown Bacterial Pathogens$1,077,232
U01 · FY2005 · AI
Electrophysiological Implications of Cardiac Bidomain$398,196
R01 · FY2005 · HL
Bioengineering$124,587
U54 · FY2005 · CA
Electrophysiological Implications of Cardiac Bidomain$404,809
R01 · FY2004 · HL
Bioengineering$155,486
U54 · FY2004 · CA
Electrophysiological Implications of Cardiac Bidomain$66,440
R01 · FY2004 · HL
Electrophysiological Implications of Cardiac Bidomain$443,094
R01 · FY2003 · HL
ELECTROPHYSIOLOGICAL IMPLICATIONS OF CARDIAC BIDOMAIN$379,586
R01 · FY2001 · HL
ELECTROPHYSIOLOGICAL IMPLICATIONS OF CARDIAC BIDOMAIN$337,034
R01 · FY2000 · HL